Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06514092

Study on the Long-Term Risk of Recurrence of Anoperineal Fistula in Crohn's Disease

Study on the Long-Term Risk of Recurrence of Anoperineal Fistula After Treatment with Anti-tumor Necrosis Factor (TNF) and Seton Drainage in Crohn's Disease : LT-SAFCD

Status
Recruiting
Phase
Study type
Observational
Enrollment
81 (estimated)
Sponsor
University Hospital, Toulouse · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This research aims to evaluate the long-term recurrence risk of perianal fistulas in Crohn's disease patients who have undergone treatment with anti-TNF therapy and seton drainage.The research seeks to identify factors influencing recurrence and assess the long term effectiveness of these treatments in preventing fistula recurrence. This study will provide insights that could enhance treatment strategies and improve patient outcomes.

Detailed description

Scientific Justification : ● Perianal fistulas are a common and challenging complication of Crohn's disease, significantly impacting patient quality of life. Infliximab, an TNFα antagonist has shown its efficacy in inducing remission of these fistulas. Seton drainage is often used alongside anti-TNF therapy to promote fistula healing and prevent abscess formation. However, data with long term follow up are still lacking on the impact of these treatments. Understanding the long-term outcomes of these combined treatments is crucial for optimizing therapeutic strategies and improving patient management. Treatment Strategy : ● The treatment involves administering infliximab to control inflammation and promote fistula closure, along with seton drainage to maintain fistula patency and prevent abscesses, ensuring continuous drainage and reducing infection risk. Follow-up Description : ● Patients are monitored retrospectively through medical records for a period ranging from several months to years, assessing recurrence rates and potential predictors of recurrence. Follow-up includes regular clinical evaluations, biological evaluations (blood test and fecal calprotectin), colonoscopy, imaging studies such as MRI, and patient-reported outcomes to gather comprehensive data on the long-term efficacy and safety of the combined treatment approach.

Conditions

Interventions

TypeNameDescription
OTHERanti-TNF therapy and seton drainageCrohn's disease patients who have undergone treatment with anti-TNF therapy and seton drainage.

Timeline

Start date
2024-09-17
Primary completion
2027-08-01
Completion
2027-08-01
First posted
2024-07-23
Last updated
2025-01-08

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT06514092. Inclusion in this directory is not an endorsement.